Low-molecular-weight heparin (LMWH):
a. Is essentially as effective therapeutically as unfractionated heparin (UFH)
b. Has the same anti-thrombin effect as UFH
c. Can be monitored using the PTT.
d. Has a shorter in vivo half-life than UFH
ANS: A
LMWH has essentially the same therapeutic efficacy as UFH. Because of its lower molecular weight, it does not have the same bridging effect as UFH, and so the antithrombin effect is reduced (not the same). For this reason, the PTT cannot be used to monitor LMWH; it is not responsive. The chromogenic anti-Xa must be used. LMWH has a longer in vivo half-life than UFH; this is one of the advantages.
You might also like to view...
CPT Appendix B is a list of add-on codes used in conjunction with other CPT codes.
Answer the following statement true (T) or false (F)
Professional standards review organizations:
A. develop scope of work programs. B. replaced PROs. C. monitor the medical necessity of hospital admissions and quality of care for CMS. D. review the appropriateness of facility services.